Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switching TDF-based regimen to abacavir-based regimen versus lopinavir/ritonavir + lamivudine in HIV-infected patients with tenofovir-induced nephrotoxicity
TCTR20190708002Phase 3Completed
- Start
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of abacavir, lopinavir + ritonavir, lamivudine, tenofovir disoproxil fumarate in human immunodeficiency virus infection (HIV), sponsored by none. Started Sep 2018; status: completed.
02
Drugs
abacavirlopinavir + ritonavirlamivudinetenofovir disoproxil fumarate
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on TCTR20190708002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20190708002.